Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Non-Current Liabilities: 2022-2025

Historic Other Non-Current Liabilities for Heron Therapeutics (HRTX) over the last 4 years, with Sep 2025 value amounting to $4.7 million.

  • Heron Therapeutics' Other Non-Current Liabilities rose 1847.72% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 1847.72%. This contributed to the annual value of $615,000 for FY2024, which is 155.19% up from last year.
  • As of Q3 2025, Heron Therapeutics' Other Non-Current Liabilities stood at $4.7 million, which was up 528.38% from $747,000 recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Other Non-Current Liabilities registered a high of $4.7 million during Q3 2025, and its lowest value of $241,000 during Q1 2022.
  • Over the past 3 years, Heron Therapeutics' median Other Non-Current Liabilities value was $241,000 (recorded in 2024), while the average stood at $765,909.
  • Data for Heron Therapeutics' Other Non-Current Liabilities shows a peak YoY skyrocketed of 1,847.72% (in 2025) over the last 5 years.
  • Quarterly analysis of 4 years shows Heron Therapeutics' Other Non-Current Liabilities stood at $241,000 in 2022, then remained steady at $241,000 in 2023, then surged by 155.19% to $615,000 in 2024, then spiked by 1,847.72% to $4.7 million in 2025.
  • Its Other Non-Current Liabilities was $4.7 million in Q3 2025, compared to $747,000 in Q2 2025 and $682,000 in Q1 2025.